Patients under cannabis-based therapies are usually chronically exposed to cannabinoids.
Introduction
Heavy and continuous cannabis use is associated with cognitive and memory impairments (Abush and Akirav, 2012; Borgelt et al., 2013) , increased probability of developing schizophrenia-spectrum disorders (Andréasson et al., 1987, Hall and Degenhardt, 2009) , acute psychosis and mania (Khan and Akella, 2009) , and amotivational syndrome (Fujiwara, 2001; Ozaki and Wada, 2001; Tunving, 1987) . Also, regular cannabis abuse can result in chronic bronchitis, impaired respiratory function and physical and significant mental dependence, tolerance and withdrawal symptoms (Lichtman and Martin, 2005; Solymosi and Köfalvi, 2017) . On the other hand, the endocannabinoid (eCB) system is involved in the regulation of several physiological processes, opening a therapeutic window to fight brain diseases (Piomelli et al., 2000) . Indeed, cannabis-based therapies are being used or proposed for refractory neurodevelopmental forms of epilepsy (Maa and Figi, 2014; Pamplona et al., 2018) , multiple sclerosis (Fitzpatrick and Downer, 2016; Rice et al., 2018) , chronic pain (Carter et al., 2015; Pascual et al., 2018) and neurodegenerative diseases (Fagan and Campbell, 2014; Basavarajappa et al., 2017; Navarro et al., 2018 ).
Major problems with prolonged therapeutic use of cannabis are the negative side-effects, thus being important to study how to mitigate such effects (Copeland et al., 2013; Lovelace et al., 2015; Solymosi and Köfalvi, 2017; Mouro et al. 2018b ).
Cannabinoids modulate neuronal function mainly via activation of the cannabinoid receptor 1 (CB 1 R) and cannabinoid receptor 2 (CB 2 R), which belong to the Gi/o family of seven transmembrane G protein-coupled receptors (GPCR) (Kano et al., 2009 ). The hippocampus, where CB 1 Rs are highly expressed (Elphick and Egertová, 2001) , is deeply involved in memory consolidation, a process that can be impaired by cannabinoid administration both in humans (Ranganathan and D'Souza, 2006; Borgelt et al., 2013; Riba et al. 2015) and in laboratory animals (Clarke et al., 2008; Kano et al., 2009; Wise et al. 2009; Sousa et al., 2011; Mouro et al., 2017; 2018b) . Ample evidence supports the involvement of CB 1 R in memory deficits (Clarke et al., 2008; Suenaga and Ichitani, 2008; Wise et al., 2009; Mouro et al., 2017) while CB 2 R agonists seem to be devoid of effect in recognition memory (Clarke et al. 2008) . The effects of cannabinoids on memory can be associated with 1) impairments in long-term potentiation (LTP) at glutamatergic synapses (Terranova et al., 1995; Misner and Sullivan, 1999; Wang et al., 2016; Silva-Cruz et al., 2017) , 2) effects on GABAergic interneurons leading to alterations in fast/slow wave oscillations, (Freund et al., 2003) , 3) signalling modifications in septalhippocampal monoaminergic and cholinergic pathways, which are responsible for regulating cortical plasticity and activity (Miller and Branconnier, 1983; Gessa et al., 1998; Redmer et al., 2003; Khakpai et al., 2013) and 4) modifications in functional connectivity between brain regions directly involved in memory and learning processes (Mouro et al. 2018b ).
Evidence has been accumulating that receptors for adenosine, another endogenous neuromodulator, may affect cannabinoid receptor functioning (Sousa et al. 2011; Ferreira et al., 2015b; Mouro et al 2017; Moreno et al., 2017) . Importantly also, adenosine A 2A receptors (A 2A R) are considered potential therapeutic targets in psychiatric disorders, given their ability to inhibit dopamine D2 receptors, to control synaptic plasticity and to modulate the action of important receptors, such as ionotropic and metabotropic glutamatergic receptors (Cunha et al., 2008; Dias et al. 2012; Mouro et al., 2018a; Temido-Ferreira et al. 2018 ). Also, facilitatory and inhibitory A 2A R-CB 1 R interactions (Ferré et al., 2010; Tebano et al., 2012; Justinová et al., 2014; Chiodi et al., 2015; Ferreira et al., 2015b ) and the formation of heteromeric complexes between these two receptors have been described in the striatum (Moreno et al., 2017) , where CB 1 R (Herkenham et al., 1990) and A 2A R (Ribeiro et al., 2003) are highly distributed. Furthermore, evidence for CB 1 -A 2A R heteromers at the hippocampus has been presented (Aso et al., 2019) . Recently we reported that A 2A R antagonists can prevent CB 1 R-mediated impairments on memory consolidation caused by a single administration of the cannabinoid receptor agonist, WIN 55,212-2 (Mouro et al. 2017 ). This time, however, we turned our attention to the chronic effects of cannabinoids. Whether the cognitive side effects resulting from chronic intake of cannabinoids could also be reverted by adenosine A 2A R antagonists is not yet known and this knowledge is of uttermost importance before suggesting A 2A R antagonists as useful therapeutic tools to mitigate side effects of cannabinoid intake for therapeutic purposes.
Therefore, we evaluated if memory deficits induced by chronic administration (30 days) of WIN 55,212-2 can be reverted by concomitant administration of KW-6002 (istradefylline), an A 2A R antagonist that can be administered orally in a prolonged way without having measurable side effects in rodents or humans, and that has already entered advanced clinical trials for other therapeutic purposes and was approved in Japan as add-on treatment for Parkinson's disease (Müller, 2015; Rascol et al., 2015) . We then searched for a mechanism involved in the interplay between A 2A R and CB 1 R in memory-related tasks and hypothesized that the influence of cannabinoid receptor agonists upon hippocampal LTP, a neurophysiological correlate of learning and memory encoding, could be modified upon A 2A R blockade. Remarkably, we found that A 2A R antagonism prevents recognition memory deficits induced by chronic exposure to the cannabinoid receptor agonist, WIN 55,212-2, and rescues the marked disruption of hippocampal LTP provoked by WIN 55,212-2. These data strongly highlight the A 2A R as a target to mitigate negative side effects of cannabinoidbased therapies involving the activation of cannabinoid receptors.
Materials and Methods

Animals
Adult (8-12 weeks old) male C57BL/6 mice (Charles River, Barcelona, Spain) were used. Animals were housed in a temperature (22/24ºC) and humidity (45-65%) regulated room with a 14/10-hour light/dark cycle (07:00-21:00) with ad libitum access to food and water. Animal behaviour experiments were performed during the light phase and around the same time each day. All experimentation followed the European Community Guidelines Animals were habituated to the presence of the investigator and handled for 5-days before testing. Animals were randomly allocated to the different treatment groups. The experimental protocol was not preregistered.
For the behavioural experiments 52 animals were used (20 for the chronic WIN 55,12-2 vs. control experiments -2 groups of 10, series 1; and 32 for KW-6002 and WIN 55,212-2 effects -4 groups of 8, divided in two series). For the radioligand binding assays, samples were gathered from 20 animals. For the electrophysiological recordings, 10 animals were used. On the behavioural experiments, the assignment of each animal to each experimental group was made through a pseudo-randomization procedure. For each set of experiments animals were tagged and distributed in groups of 5 animals to each housing cage. Cages were randomly attributed to each treatment condition. To do so, a number was attributed to each cage and randomly drawn. Drawn cage numbers were distributed sequentially to either group (for instance, first drawn number allocated to control, the second drawn number attributed to experimental group, until all numbers have been drawn). For details on experimental groups, see figure 1.
Drugs
KW-6002 (istradefylline) was synthesized according to a published procedure (Hockemeyer et al., 2004) . SCH 58261 (7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5 c]pyrimidine), was obtained from Sigma-Aldrich (MO, USA).
were obtained from Tocris Bioscience. WIN 55,212-2 and SCH 58261 were suspended in dimethylsulfoxide (DMSO) at stock concentrations of 100 mM, and 5 mM, respectively, carefully sonicated, aliquoted and stored at -20ºC. For the behavioural procedures, appropriate dilutions of these solutions were made in saline (NaCl 0.9%) before injection.
KW-6002 (3 mg/kg/day, 0.025% methylcellulose) was diluted in the drinking water.
Considering an average volume of water intake of 4.5 ml per day per mouse, an average bodyweight of 25 g, and a daily dose of KW-6002 of 3 mg/kg body weight, the average concentration of KW-6002 in the drinking water was 0.017mg/ml, thus 44µM. It is important to note that the animals were weighted weekly, that the water consumption in each cage was also monitored weekly, and that the concentration was weekly adjusted to keep the dose at 3 mg/kg of body weight per day. Minor deviations could occur between the animals within each cage (housed 5 per cage), since volume intake was monitored per cage, being impossible to monitor per animal. However, due to the lack of marked differences in the body weight of different animals within the cage as well as throughout the treatment, it is unlikely that marked differences in water intake occurred. Weekly changes in body weight were also minor due to the fact that animals were already adults when starting the treatment. is known to affect memory through CB 1 R activation, without creating sedative or cataleptic effects that are associated with higher doses (Schneider and Koch, 2003; Yim et al., 2008; Baek et al., 2009) . Behavioural tests were carried out on the last five days of treatment. The injections were performed around the same hour of the day (18:00 ± 1 hour), while behavioural tests were performed during the morning (10:00). Doing so, we avoided withdrawal symptoms (Maldonado, 2002; Lichtman and Martin, 2005; Solymosi and Köfalvi, 2017) , while minimizing acute effects of the drug during testing. In order to replicate a pattern of chronic intermittent cannabinoid exposure (Lamarque et al., 2001; Schneider and Koch, 2003) animals were treated for 5 consecutive days followed by two days without treatment (22 injections over 28 days). This protocol was designed to minimize the tolerance to WIN 55,212-2 that may develop during chronic continuous administration (Maldonado, 2002; Solymosi and Köfalvi, 2017) . For further details on the treatment and experimental protocol see Figure 1 .
Chronic Treatment with KW-6002
KW-6002 dose was selected according to previous testing of the efficacy and selectivity of this drug after oral administration (Yang et al., 2007; Batalha et al., 2013; Mouro et al., 2017) ; it was diluted in the drinking water (3 mg/kg/day) and administered for (Figure 1 ). Therefore, data from the same group in the two series was pooled altogether, as done before (Mouro et al. 2017 ). In both series, animals were randomly divided into 4 groups with equal number of animals (10). As mentioned before, cages were randomly attributed to each experimental group in a pseudo-randomization process.
Novel Object Recognition Test
NORT was conducted in a square open field arena (40 × 40 × 40 cm) made out of wood as previously reported (Bailey and Crawley, 2009; Antunes and Biala, 2012 , Mouro et al. 2017 , 2018b . In brief, the test involved a habituation period (3 days), a training day and a test day. Before training, animals were habituated to the arena in the absence of any stimulus or object, under the same lighting and environmental conditions, for 20 minutes over 3 consecutive days. On the fourth day the animals were placed inside the arena, facing away from the two identical objects (familiar objects) and allowed to freely explore the environment and objects for 5 minutes. After a retention interval of 24 hours, to test longterm memory (Clarke et al. 2008; Antunes and Biala, 2012) , animals were placed inside the arena, with one novel and one familiar object (test day). Animals were allowed to explore the objects for 5 minutes, after which they were removed from the arena. The objects used in the training and test days were wooden dolls (7 cm height × 6 cm width). The role of the object, as either familiar or novel, was randomized as was the location of their presentation.
To randomize the role of the object a blind experimenter was asked to randomly select one of the objects to be the novel object for the first animal. Then, for the subsequent animal testing, the novel object was permuted, to ensure that both objects were used as the novel object the same number of times in both the control and the experimental groups. Between every trial, the arena and the objects were carefully cleaned with a 30% ethanol solution to erase any olfactory clues. The objects were secured to the bottom of the arena with a piece of Velcro that could not be seen or touched by the animals. The objects were placed in symmetric and opposed corners of the arena. Activity was recorded using the videotracking software -SMART®. To refine the results obtained by software measures, a postanalysis was conducted. In the post-analysis, the investigator was blind to the experimental condition. Exploratory behaviour was quantified as the amount of time (seconds) animals spent investigating each object (only direct approaches were considered; ≤ 1 cm distance).
The number of approaches that included sniffing the object, rearing towards the object or touching the object, were counted (Antunes and Biala, 2012; Ennaceur, 2010; Ennaceur and Delacour, 1988) . Exploration of each object was quantified as the novelty preference index (NPI) -calculated as (B-A) / (B+A), where B corresponds to the time spent exploring the novel object and A the time spent exploring the familiar object, during the test phase of NORT. This index thus ranges from -1 to 1 (-1 = exclusive exploration of the familiar object; 0 = absence of discrimination between novel and familiar objects, i.e. equal time exploring both objects, and 1 = exploration of the novelty only). We defined full immobility during the test stage of NORT as an a priori exclusion criterion. Following this criterion, there were no animals to be excluded from the sample. No significant outliers were detected.
Open field test (OF) and Elevated Plus Maze (EPM)
Anxiety-like and locomotor behaviour were analysed in the OF test and EPM.
Behaviour in the OF test was analysed before the NORT. The OF test was used to assess individual behaviour when animals are placed in a novel environment (Wilson et al., 1976) , as well as anxiety (Careau et al., 2012) . Since locomotor activity can impact exploratory drive (Broadhurst, 1958 (Broadhurst, , 1957 Stanford, 2007) , it was important to ascertain that animals did not display significant differences in locomotor activity. The OF test took place in the same arena as that used for the NORT (square open field arena: 40 × 40 × 40 cm) and activity was recorded during the first time that animals had contact with the environment, i.e., on the first 5 minutes of the first day of NOR habituation phase (see Figure 1 ). To quantify behaviour, the percentage of time spent in the central zone of the arena was used as an indicator of anxiety (see Mouro et al. 2017 Mouro et al. , 2018b . Mean velocity and distance travelled were quantified to compare locomotor abilities between the experimental groups.
Activity was recorded and analysed using the video-tracking software -SMART®. The reference point used by the software to determine the position of the animal was the centre of the mouse dorsum, as before (Coelho et al., 2014; Mouro et al., 2017) . Environmental conditions and animal manipulation procedures were kept as similar as possible between animals. During test phase of the NORT, the total time spent exploring the objects was used as a measure of locomotor activity/exploratory drive.
Anxiety-like behaviour was also assessed in the EPM. Immediately after being tested in the NORT during the test day (see anxiety-like behaviour (Pellow et al., 1985; Coelho et al., 2014; Mouro et al., 2017 Mouro et al., , 2018b .
Field Excitatory Postsynaptic Potential Recordings
The experiments were performed in acute transverse hippocampal slices. After decapitation, the brain was rapidly removed and both hippocampi dissected free in ice-cold artificial cerebrospinal fluid (aCSF) solution with the following composition (in mM): NaCl 124; KCl 3; NaH 2 PO 4 1.25; NaHCO 3 26; MgSO 4 1; CaCl 2 2; and D-glucose 10, previously gassed with 95% O 2 and 5% CO 2 , pH 7.4. Slices (400 μm thick) were obtained using a McIlwain tissue chopper, were allowed to recover in aCSF for at least one hour at room temperature, and kept in such conditions until use. Since the time course of the effect of WIN 55,212-2 on hippocampal synapses is rather slow (Serpa et al., 2009) , WIN 55,212-2 (300 nM) was incubated with the slices for one hour before the setting up for electrophysiological recordings. When used, SCH 58261 (100 nM) was incubated for half hour before adding WIN 55,212-2 in its presence. All the incubations were done at room temperature and in gassed aCSF. After incubation period, slices were superfused with aCSF (3 mL/min) at 32ºC for fEPSPs recordings in the CA1 area as before (Diógenes et al., 2012; Ferreira et al., 2015a) . LTP was induced by a theta-burst protocol (10 trains with 4 pulses each at 100 Hz, separated by 200 ms) and only after obtaining at least a 10-minute steady baseline of fEPSP slope values. LTP was quantified as the % change in the average slope of fEPSP taken from 40-50 minutes after LTP induction in relation to the average slope of the fEPSP measured during the baseline period.
Radioligand Binding
The amount of tissue allowed a single point radioligand binding which was carried out with slight modification to our previous studies (Ferreira et al., 2015b; Leffa et al., 2018) .
The prefrontal cortices and the hippocampi were isolated from the mice and collected and homogenized in 1.8 mL of ice-cold membrane preparation solution of the following composition: sucrose (320 mM), EDTA (2 mM), MgCl 2 (3 mM), HEPES (15 mM), pH 7.4, supplied with a protease inhibitor cocktail (Sigma-Aldrich, 1 µL/mL). The homogenates were then centrifuged at 1000 g for 30 min, at 4 ºC to decant intracellular debris. The membrane-rich supernatant was then recentrifuged at 20,000 g for 30 min, and the pellets were vigorously resuspended in binding assay buffer of the following composition: NaCl 
Statistical Analysis
Data are expressed as means ± SEM. All data sets were tested for normality and analysed in GraphPad Prism 6 software. A test for outliers was performed using the Graphpad Outlier Calculator. NORT, OF and EPM data were analysed using two-tailed, paired or unpaired Student's t-tests, or one-way ANOVA, as appropriate for each condition and as indicated in the figure legends. To analyse interaction between different treatments a two-way ANOVA was used. For data obtained in electrophysiological experiments or radioligand-binding assays, t-test or one-way ANOVA were used, as appropriate for each analysis. When using ANOVA, Tukey's pot-hoc multiple comparisons tests were performed.
Results
KW-6002 and WIN 55,212-2 treatments do not affect A 2A R and CB 1 R distribution
We first assessed whether chronic intake of WIN 55,212-2 or KW-6002 would affect the density of their own receptor targets. To do so, we quantified the specific binding by others while using mice (Temido-Ferreira et al. 2018) , though in rats a small enhancement has been reported (Batalha et al., 2013) . We can thus preclude major influences of prolonged drug treatments upon the expression of their own receptor targets.
KW-6002 prevents disruption of recognition memory caused by chronic administration of WIN 55,212-2
Chronic exposure to the CBR agonist WIN 55,212-2 disrupted recognition memory evaluated in the NORT. As expected, in the training phase, control animals (saline solution)
and animals chronically treated with WIN 55,212-2 (1 mg/kg), explored approximately the same amount of time the two identical objects ( figure 3, panel a.) . However, in the test day et al. 2018b) , the impairment in the NORT was not accompanied by significant modifications in anxiety-like behaviour or impairments in locomotion, which were assessed before, after and during the NORT, using respectively, the OF, the EPM, and measuring the total time of exploration (TTE) during the test phase of the NORT; no statistically significant differences were detected in any of the quantified parameters (figure 3, panels d.
for TTE, e. for EPM and f. for OF).
To understand if the negative effects of WIN 55,212-2 on memory in adult mice are reversible, animals were tested again 1 month after stopping WIN 55,212-2 administration, using different pairs of objects. Interestingly, animals that had been previously chronically treated with WIN 55,212-2 displayed behaviour similar to control animals, exploring more the novel object than the familiar one (p < 0.05, paired Student's t-test to compare % of time spent with familiar vs. novel object, n = 10 for each group). These results show that, in contrast with what occurs when exposure to the cannabinoid occurs during adolescence (Schneider et al. 2008 ) the effects of chronic administration of WIN 55,212-2 on recognition memory are reversible when exposure occurs during the adulthood. These differences might be related with age-specific differences in the endocannabinoid system and its impact in brain maturation (Schneider et al., 2008; Maldonado, 2002; Lichtman and Martin, 2005) . 
A 2A R blockade attenuates WIN 55,212-2-mediated LTP impairments
In search for a mechanism involved in the ability of an Altogether these results show that in the presence of an SCH 58261 the inhibition caused by WIN 55,221-2 upon LTP is significantly attenuated, thus suggesting that by A 2A R blockade is able to prevent the disruptive effects of a cannabinoid receptor agonist upon synaptic plasticity.
Discussion
In (Ferré et al., 2010; Tebano et al., 2012; Chiodi et al., 2015; Ferreira et al., 2015b; Moreno et al., 2017; Mouro et al., 2017; Aso et al., 2018) but reinforces the idea that side effects of prolonged cannabinoid intake, as memory impairment, can be mitigated by A 2A R antagonism.
The relevance of this work is related with a well-documented increase in prolonged and sustained cannabis use, both for recreational and therapeutic purposes (Hall, 2015; Lichtman and Martin, 2005) . It is firmly established that prolonged abuse of cannabis for recreative reasons can lead to negative consequences on cognition, brain functioning, mental health and respiratory functioning (Solymosi and Köfalvi, 2017) . On the other hand, prolonged cannabis-based therapies, specifically when involving the use of CB 1 R agonists, such as Δ 9 -tetrahidrocanabinol (Δ9-THC), can lead to memory and cognitive impairments, as frequently reported (Borgelt et al., 2013) . Therefore, the decision of using cannabisbased drugs usually implies that the benefits of the therapeutic intervention outweighs its possible negative consequences. The results herein displayed have potential therapeutic implications, as they show that istradefylline (KW-6002), a drug therapeutically used in Parkinson's disease (Sako et al., 2017) , can tackle a negative side effect of prolonged cannabinoid use.
In this work we did not evaluate the specificity of the cannabinoid receptor responsible for the effects observed in the behaviour experiments. However, previously, we have shown that the detrimental effects on recognition memory following acute WIN 55,212-2 administration are mediated by CB 1 R activation (Mouro et al. 2017) . WIN 55-212,2-2 is a commonly used cannabinomimetic (Solymosi and Köfalvi, 2017 ) with a particularly favourable profile for use in behavioural experiments. WIN 55,212-2 can be dissolved in DMSO and injected with physiological saline, the required DMSO concentrations being innocuous for mice (Castro et al., 1995) . WIN 55,212-2 is widely used in animal models to study the cannabinoid effects on several different processes, such as, dependence (Aguilar et al., 2017; Bambico et al., 2010; Schneider and Koch, 2003) , emotion and social behaviour (Schneider et al., 2008; Zamberletti et al., 2014) , depressivelike behaviour and anhedonia (Rubino et al., 2008) , anxiety (Rubino and Parolaro, 2016) and memory (Schneider et al., 2008; Clarke et al., 2008; Suenaga and Ichitani, 2008; Yim et al., 2008) . Although WIN 55,212-2 shows similar affinity for activating both CB 1 R and CB 2 R (Pertwee et al., 2010) , evidence supports that CB 1 R activation is responsible for the memory deficits induced by cannabinoids (Clarke et al 2008 , Mouro et al. 2017 ) and that CB 2 R are not responsible for deficits in recognition memory (Clarke et al. 2008 ).
Evidence of the consequences of chronic exposure to cannabinoids is usually evaluated during adolescence, since it is a particularly vulnerable time window for exocannabinoid actions (Schneider et al., 2008) . Using mice models, it has been shown that chronic cannabinoid exposure can lead to worse effects in adolescent rats comparing with adult animals (Schneider and Koch 2003; Schneider et al., 2008) . However, as we previously demonstrated, even in adult mice, chronic administration of WIN 55,212-2 leads to impairments in recognition memory, induces modifications in brain metabolism and results in alterations in brain connectivity between several brain regions involved in recognition memory (Mouro et al. 2018b ), thus highlighting that the possible negative impact of chronic cannabinoid exposure in the brains of adult users should not be neglected.
The effects of cannabinoids on memory have been associated with impairment of synaptic plasticity, namely in long-term potentiation (LTP) at glutamatergic synapses (Terranova et al., 1995; Stella et al., 1997; Misner and Sullivan, 1999; Wang et al., 2016; Silva-Cruz et al., 2017) . Consequences of cannabinoid receptor activation on LTP have been thoroughly investigated in the hippocampus (Freund et al., 2003) since this brain area is deeply associated with learning and memory (Scoville and Milner, 1957) and that has intense CB 1 R binding (Piomelli, 2003) . While endocannabinoids may affect plasticity in a dual way, reinforcing strong synapses and inhibiting weakly reinforced ones, thus acting like an high pass filter to increase signal to noise ratio of plasticity (Silva-Cruz et al., 2017) , the effect of exogenous activation of CB 1 Rs is consistently reported as inhibitory (Bohme et al., 1999; Misner and Sullivan, 1999; Carlson et al., 2002; Davies et al., 2002; Jacob et al., 2012; Wang et al., 2016) further highlighting the consequences of perturbing a fundamental role of the endocannabinoid system in regulating synaptic plasticity (Piomelli, 2003) . Remarkably, as we now show, the A 2A R antagonist SCH 58261 markedly attenuates LTP impairments mediated by WIN 55,212-2. Interestingly, upon a single administration of a cannabinoid receptor agonists and a single administration of A 2A R receptor antagonist, A 2A R antagonists seem to act by rescuing memory consolidation rather than by facilitating retrieval (Mouro et al., 2017) . As hippocampal LTP is considered the physiological substrate of learning and memory consolidation, the ability of SCH 58261 to partially restore LTP impairments induced by WIN 55,212-2 may represent the synaptic mechanism responsible for the protective role of A 2A R antagonists against cannabinoid-mediated memory impairments. Nevertheless, due to the ample distribution of the CBR in the brain and the involvement of several key brain areas in recognition memory (Warburton and Brown, 2015, Mouro et al. 2018b) , the effects of cannabinoids on memory also likely reflect a more complex modifications in the brain, including changes in brain network connectivity (Mouro et al. 2018b ).
In conclusion, the present evidence that an A 2A R antagonist is able to tackle negative effects on memory caused by prolonged intake of cannabinoids highlights the possibility to prevent those negative effects upon cognition, whenever cannabinoids might be required as putative therapeutics. Protocol for WIN 55,212-2 administration was as in protocol 1. KW-6002, or its vehicle, was kept available in the drinking water for the entire 28-day period. As in protocol 1, behavioural tests were performed 22-24h after the last WIN 55,212-2 injection. These results allow to preclude increases in anxiety and locomotion impairments as possible confoundable variables in the main effects observed in the NORT. 
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